Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 1
1991 1
1994 1
1995 1
1998 1
1999 2
2000 2
2004 1
2005 2
2006 4
2007 7
2008 5
2009 3
2010 7
2011 14
2012 31
2013 19
2014 25
2015 47
2016 51
2017 37
2018 38
2019 24
2020 25
2021 23
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

369 results
Results by year
Filters applied: . Clear all
Page 1
Immunological Aspects of Approved MS Therapeutics.
Rommer PS, Milo R, Han MH, Satyanarayan S, Sellner J, Hauer L, Illes Z, Warnke C, Laurent S, Weber MS, Zhang Y, Stuve O. Rommer PS, et al. Among authors: weber ms. Front Immunol. 2019 Jul 11;10:1564. doi: 10.3389/fimmu.2019.01564. eCollection 2019. Front Immunol. 2019. PMID: 31354720 Free PMC article. Review.
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: weber ms. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group. Montalban X, et al. Among authors: weber ms. N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. N Engl J Med. 2019. PMID: 31075187 Clinical Trial.
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Stangel M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Hunter ZR, Kallmann B, Kleinschnitz C, Klotz L, Leussink V, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber MS, Weber F, Zettl UK, Ziemssen T, Zipp F; die Multiple Sklerose Therapie Konsensus Gruppe (MSTKG). Wiendl H, et al. Among authors: weber ms. Nervenarzt. 2021 Aug;92(8):773-801. doi: 10.1007/s00115-021-01157-2. Epub 2021 Jul 23. Nervenarzt. 2021. PMID: 34297142 Free PMC article. Review. German.
Targeting B cells in multiple sclerosis.
Sellebjerg F, Weber MS. Sellebjerg F, et al. Among authors: weber ms. Curr Opin Neurol. 2021 Jun 1;34(3):295-302. doi: 10.1097/WCO.0000000000000938. Curr Opin Neurol. 2021. PMID: 33782253 Review.
Statins and demyelination.
Weber MS, Zamvil SS. Weber MS, et al. Curr Top Microbiol Immunol. 2008;318:313-24. doi: 10.1007/978-3-540-73677-6_12. Curr Top Microbiol Immunol. 2008. PMID: 18219823 Review.
Immunopathogenesis of neuromyelitis optica.
Levy M, Wildemann B, Jarius S, Orellano B, Sasidharan S, Weber MS, Stuve O. Levy M, et al. Among authors: weber ms. Adv Immunol. 2014;121:213-42. doi: 10.1016/B978-0-12-800100-4.00006-4. Adv Immunol. 2014. PMID: 24388217 Review.
369 results